Merck KGaA (ADR)
General ticker "MKKGY" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $61.1B (TTM average)
Merck KGaA (ADR) follows the US Stock Market performance with the rate: 59.9%.
Estimated limits based on current volatility of 0.9%: low 29.84$, high 30.41$
Factors to consider:
- Company pays dividends (annually): last record date 2026-04-28, amount 0.51$ (Y1.69%)
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [21.49$, 32.18$]
- 2026-12-31 to 2027-12-31 estimated range: [21.82$, 32.67$]
Financial Metrics affecting the MKKGY estimates:
- Positive: with PPE of 12.7 at the end of fiscal year the price was neutral
- Positive: 6.77 < Operating cash flow per share per price, % of 7.15
- Positive: 15.80 < Operating profit margin, % of 19.26
- Positive: 49.86 < Shareholder equity ratio, % of 54.88 <= 58.56
- Negative: Industry earnings per price (median), % of 0 <= 0
- Negative: Investing cash flow per share per price, % of -7.75 <= -7.11
- Positive: Interest expense per share per price, % of 0.48 <= 0.75
- Negative: Return on assets ratio (scaled to [-100,100]) of 4.60 <= 5.14
- Negative: negative Industry operating cash flow (median)
Short-term MKKGY quotes
Long-term MKKGY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €20,993.00MM | €21,156.00MM | €20,269.16MM |
| Operating Expenses | €17,384.00MM | €17,511.00MM | €16,364.60MM |
| Operating Income | €3,609.00MM | €3,645.00MM | €3,904.57MM |
| Non-Operating Income | €-125.00MM | €-109.00MM | €-727.12MM |
| Interest Expense | €272.00MM | €292.00MM | €251.66MM |
| R&D Expense | €2,445.00MM | €2,279.00MM | €2,287.99MM |
| Income(Loss) | €3,484.00MM | €3,536.00MM | €3,177.44MM |
| Taxes | €650.00MM | €751.00MM | €665.65MM |
| Net Income(Loss)* | €2,824.00MM | €2,777.00MM | €2,505.07MM |
| Stockholders Equity | €26,680.00MM | €29,912.00MM | €28,579.83MM |
| Inventory | €4,637.00MM | €4,484.00MM | €4,560.06MM |
| Assets | €48,495.00MM | €51,567.00MM | €52,077.83MM |
| Operating Cash Flow | €3,784.00MM | €4,586.00MM | €3,776.81MM |
| Capital expenditure | €2,023.00MM | €2,184.00MM | €1,521.48MM |
| Investing Cash Flow | €-1,892.00MM | €-3,050.00MM | €-4,092.83MM |
| Financing Cash Flow | €-1,732.00MM | €-985.00MM | €603.21MM |
| Earnings Per Share** | €1.30 | €1.28 | €1.15 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.